Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen Migraine Pain (Motrin Migraine Pain), cromolyn sodium nasal spray (Nasalcrom) and ibuprofen cold & sinus (Advil Cold & Sinus) are among the private-label products in the pipeline; however, the granting of pediatric exclusivity could set back their launch. Upcoming supplements from Perrigo include MSM with glucosamine, bone & joint gelatin powder (NutraJoint), calcium 600 + soy, a multivitamin with lutein, FreeFlex glucosamine (Aflexa) and two glucosamine/chondroitin products (Flexagen and Osteo-Bi-Flex) (1see related story, p. 14)
Advertisement

Related Content

Leiner OTC Sales Buoy Company Performance As Supplement Market Slows
Leiner OTC Sales Buoy Company Performance As Supplement Market Slows
Leiner OTC Sales Buoy Company Performance As Supplement Market Slows
Flexagen Joint Care "From The Makers of Advil " Hitting Shelves Now
Flexagen Joint Care "From The Makers of Advil " Hitting Shelves Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS091383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel